E-LIB Suche - Ergebnisse für: Gallego‐Hernanz, Pilar

1

Hypomethylating agent monotherapy in core binding factor ac..:

Gabellier, Ludovic ; Peterlin, Pierre ; Thepot, Sylvain...
Annals of Hematology. 103 (2024) 3 - p. 759-769 , 2024

Link: https://doi.org/10.1007/..

2

Safety of empirical antibiotic therapy discontinuing for fe..:

Clément, Lemaigre ; Hélène, Deutch ; Maud, Meligne...
Journal of Infection. 88 (2024) 6 - p. 106171 , 2024

Link: https://doi.org/10.1016/..

3

Bacteremia due to Lachnoanaerobaculum umeaense in a patient..:

Bodin, Julie ; Gallego-Hernanz, Maria-Pilar ; Plouzeau Jayle, Chloé...
Journal of Infection and Chemotherapy. , 2024

Link: https://doi.org/10.1016/..

4

Combination of azacitidine, venetoclax and ruxolitinib in b..:

Systchenko, Thomas ; Chomel, Jean‐Claude ; Gallego‐Hernanz, Pilar...
British Journal of Haematology. 202 (2023) 2 - p. 284-288 , 2023

Link: https://doi.org/10.1111/..

5

Impact of central nervous system involvement in adult patie..:

Orvain, Corentin ; Chantepie, Sylvain ; Thomas, Xavier...
Haematologica. 108 (2023) 12 - p. 3287-3297 , 2023

Link: https://doi.org/10.3324/..

6

Genetic alterations and MRD refine risk assessment within K..:

Kim, Rathana ; Bergugnat, Hugo ; Pastoret, Cedric...
info:eu-repo/semantics/altIdentifier/doi/10.1182/blood.2023021501. , 2023

Link: https://univ-rennes.hal...

7

Genetic alterations and MRD refine risk assessment within K..:

Kim, Rathana ; Bergugnat, Hugo ; Pastoret, Cedric...
info:eu-repo/semantics/altIdentifier/doi/10.1182/blood.2023021501. , 2023

Link: https://univ-rennes.hal...

8

Combination of azacitidine, venetoclax and ruxolitinib in b..:

Systchenko, Thomas ; Chomel, Jean‐claude ; Gallego-Hernanz, Pilar...
info:eu-repo/semantics/altIdentifier/doi/10.1111/bjh.18853. , 2023

Link: https://hal.science/hal-..

9

Genetic alterations and MRD refine risk assessment within K..:

Kim, Rathana ; Bergugnat, Hugo ; Pastoret, Cedric...
info:eu-repo/semantics/altIdentifier/doi/10.1182/blood.2023021501. , 2023

Link: https://univ-rennes.hal...

10

Genetic alterations and MRD refine risk assessment within K..:

Kim, Rathana ; Bergugnat, Hugo ; Pastoret, Cedric...
info:eu-repo/semantics/altIdentifier/doi/10.1182/blood.2023021501. , 2023

Link: https://univ-rennes.hal...

11

Combination of azacitidine, venetoclax and ruxolitinib in b..:

Systchenko, Thomas ; Chomel, Jean‐claude ; Gallego-Hernanz, Pilar...
info:eu-repo/semantics/altIdentifier/doi/10.1111/bjh.18853. , 2023

Link: https://hal.science/hal-..

12

Genetic alterations and MRD refine risk assessment within K..:

Kim, Rathana ; Bergugnat, Hugo ; Pastoret, Cedric...
info:eu-repo/semantics/altIdentifier/doi/10.1182/blood.2023021501. , 2023

Link: https://univ-rennes.hal...

13

Genetic alterations and MRD refine risk assessment within K..:

Kim, Rathana ; Bergugnat, Hugo ; Pastoret, Cedric...
info:eu-repo/semantics/altIdentifier/doi/10.1182/blood.2023021501. , 2023

Link: https://univ-rennes.hal...

14

Genetic alterations and MRD refine risk assessment for KMT2..:

Kim, Rathana ; Bergugnat, Hugo ; Pastoret, Cédric...
boreal:282178. , 2023

Link: http://hdl.handle.net/20..

15

Genetic alterations and MRD refine risk assessment within K..:

Kim, Rathana ; Bergugnat, Hugo ; Pastoret, Cedric...
info:eu-repo/semantics/altIdentifier/doi/10.1182/blood.2023021501. , 2023

Link: https://univ-rennes.hal...